| Quick Answer |
| Supervised weight loss programs in India rely mainly on two GLP-1 medications given as once-weekly injections: semaglutide and tirzepatide, which act on both GLP-1 and GIP. Orlistat, an older capsule, is the third medicine approved here for weight management. A doctor checks eligibility, raises the dose in steps, monitors bloods and side effects, and decides how long treatment runs. |
The Medicines (semaglutide, tirzepatide, others)
The real weight loss drugs list in India is shorter than your Instagram feed suggests. The Health Ministry has named three medicines CDSCO has approved for obesity and weight management: orlistat, tirzepatide and semaglutide.
Semaglutide copies GLP-1, a gut hormone your body releases after a meal. It tells the brain you have eaten enough and slows how quickly the stomach empties, so a plate of rajma chawal keeps you full for longer. For weight management, it is a once-weekly injection. Since its Indian patent lapsed in March 2026, several Indian manufacturers have launched their own versions of the same molecule, as Deccan Herald reported while covering the Center’s tighter watch on how these drugs are promoted.
A new brand name on the box does not change how the medicine behaves. Generic semaglutide is the same molecule, with the same dose ladder, the same side effects and the same need for follow-up, and it is still prescription-only.
Tirzepatide works on two hormone receptors, GLP-1 and GIP. In India it comes as single-dose vials and a multi-dose pen, according to CDSCO’s June 2026 expert committee minutes.
That second hormone signal is the main design difference between the two injections. Both slow the stomach and quieten appetite; tirzepatide adds a GIP effect that also plays a part in how the body handles sugar and stored fat.
In the STEP 1 and SURMOUNT-1 trials, some participants lost up to 20% of their body weight. Individual results vary widely.
Orlistat is a different kind of medicine. It works inside the gut, blocking the enzymes that digest fat, so part of the ghee and oil you eat leaves the body undigested. In the four-year XENDOS trial, it also lowered the number of people with obesity who went on to develop type 2 diabetes.
Orlistat is taken with meals that contain fat. After a light plate of poha or dal-chawal, it has little to block, while a heavy, oily thali tends to bring the side effects on quickly, which nudges many people toward lighter cooking. Because it reduces fat absorption, it can also lower the uptake of fat-soluble vitamins A, D, E and K, so doctors often suggest a multivitamin taken at a separate time of day.
Then there are the medicines people ask about by name. The revised Indian obesity guidance by Misra and colleagues (2025) notes that liraglutide, dulaglutide and oral semaglutide are licensed in India for type 2 diabetes only, and that the 3 mg weight-management strength of liraglutide is not available here.
Taking a diabetes-only medicine purely to lose weight, or ordering an injection online without a consultation, skips the checks that make treatment safe. Regulators have noticed: CDSCO has asked state drug controllers to watch the supply chain for these medicines more closely.
How Doctors Choose the Right One
The first question is eligibility, and here India has two sets of numbers. Both injections were tested in adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as hypertension or type 2 diabetes, and their approved indications follow those trial criteria.
In clinic, a doctor reads these numbers alongside a measuring tape. Two people with the same BMI of 27 can look very different on the inside. One carries weight evenly; the other carries it around the belly, with a fatty liver and an HbA1c that creeps up every year. The second person usually has more to gain from treatment.
Indian clinical guidance draws the line lower. The 2009 Indian consensus treated a BMI of 23 as overweight and 25 as obesity, with a waist of 90 cm in men and 80 cm in women marking abdominal obesity. The 2025 revision goes further and defines obesity from a BMI above 23, staged by waist size, waist-to-height ratio and health effects.
The gap is not academic. The ICMR-INDIAB study estimated 254 million Indian adults with generalized obesity and 351 million with abdominal obesity. In June 2026, CDSCO’s expert committee declined a request to remove the BMI cut-off from tirzepatide’s indication, noting that obesity is defined differently in Asian and US populations.
Within those limits, the choice depends on the person. A doctor weighs diabetes status, heart history, any past pancreatitis or gallbladder trouble, other medicines, and how well your stomach copes. A personal or family history of medullary thyroid cancer rules out both injections, according to their prescribing information.
Life stage matters as well. These injections are not used during pregnancy, and the labels advise stopping them ahead of a planned pregnancy, so anyone trying to conceive or breastfeeding needs a different plan. A history of eating disorders also changes the conversation.
Tirzepatide vs semaglutide: which is better? There is no single winner for everyone. In SURMOUNT-5, the first head-to-head trial, adults without diabetes on tirzepatide lost more weight on average over 72 weeks, and fewer stopped treatment because of stomach side effects.
It helps to know what that trial was and was not. It was open-label, it ran at sites in the United States, it was funded by the maker of tirzepatide, and it left out people with type 2 diabetes. None of that makes the result wrong, but it is one reason doctors still treat the choice as individual.
Semaglutide brings a different strength. The SELECT trial found fewer heart attacks, strokes and cardiovascular deaths in people with overweight or obesity and existing heart disease. For a 48-year-old in Pune who had a stent put in last year, that evidence can carry real weight in the decision.
Practical questions count too: how often you can come in for reviews, whether you are comfortable injecting at home, and how your stomach handled earlier diabetes medicines. A good program talks these through before the first dose.
Dose Titration Explained
Both injections start low and climb slowly. The pauses between steps give your gut time to adjust, because nausea, vomiting, diarrhea, and constipation tend to cluster in the weeks after each increase.
Titration also gives the doctor information. How you feel at each step shows whether the next step is worth taking or whether a lower dose is already doing the job. Some users never need the top dose.
How is the Mounjaro dose increased? Mounjaro dosage starts at 2.5 mg once a week for four weeks. That first dose only gets the body used to the drug and is not a treatment dose. The doctor then moves you to 5 mg and can add 2.5 mg at a time, with at least four weeks at each level, up to 15 mg. Maintenance usually settles at 5, 10 or 15 mg, per the tirzepatide prescribing information.
The Wegovy dose follows a fixed monthly ladder: 0.25 mg in weeks 1 to 4, 0.5 mg in weeks 5 to 8, 1 mg in weeks 9 to 12, 1.7 mg in weeks 13 to 16, and 2.4 mg from week 17 onward. If side effects bite, the semaglutide label lets the doctor hold a step for longer.
Each label has its own rules for missed doses, and the safest move is to ask your doctor rather than double up. After a gap of a couple of weeks, going straight back to the old dose can bring the nausea back, so the doctor may step you down and climb again.
Rushing the ladder mostly buys extra nausea.
Simple habits make each step easier: smaller meals, eating slowly and stopping at the first sense of fullness. In the first days after a dose increase, a bowl of curd rice or moong dal khichdi usually sits better than a plate of chole bhature.
One label detail matters for many Indian women, including those managing PCOS. Tirzepatide can make oral contraceptive pills less reliable, so a backup method is advised for four weeks after starting and for four weeks after every step-up.
Tell your doctor about every other medicine you take, including tablets for thyroid, blood pressure or blood thinning. Because these injections slow the stomach, they can change how some oral medicines are absorbed.
What’s Monitored During Treatment
What tests are needed while on weight loss injections? Most programs begin with a baseline panel. The 2025 Indian obesity guidance lists HbA1c, a fasting lipid profile, liver and thyroid function tests, blood urea, serum creatinine, and uric acid in its work-up, tailored to each person.
Follow-ups then track weight, waist, and blood pressure, along with how you are eating and coping with the dose. If you take insulin or a sulfonylurea for diabetes, sugar checks get closer, because combining them with these injections raises the risk of low blood sugar.
How often you are seen varies by program. Many doctors review more closely during the escalation months, when side effects are most likely, and space visits out once the dose and weight are steady.
Most GLP-1 side effects are digestive and settle with time. A few need a call to your doctor the same day: severe, persistent upper-abdominal pain that can spread to the back (possible pancreatitis), pain under the right ribs or yellowing eyes (gallbladder), and vomiting bad enough to leave you dehydrated, which can strain the kidneys. People with diabetic eye disease also need eye checks, since the semaglutide label flags retinopathy complications.
Fluids are a quiet safeguard. Appetite drops on these medicines, and for many people so does thirst, which matters in Mumbai or Chennai humidity. The Indian expert consensus suggests about 2 litres a day of water or unsweetened drinks such as plain buttermilk or nimbu pani, unless your doctor has set a different limit.
Muscle is the quieter thing to watch. South Asians tend to carry less lean mass for their size, and an Indian expert consensus published in 2026 recommends a nutrition assessment before starting, simple strength tests such as handgrip and chair-stand for people at risk, and periodic checks for vitamin D, B12 and iron when intake drops.
Weight that comes off is never pure fat. In the body-composition sub-studies that consensus summarises, lean mass made up a real share of the loss, which is why resistance exercise sits alongside the medicine. Chair squats, resistance bands at home, or a few gym sessions a week all count.
On the plate, that usually means protein at every meal from dal, chana, rajma, paneer, dahi, eggs or fish. The Dietary Guidelines for Indians favor getting protein from food combinations such as dal with rice or roti over heavy use of protein powders. The Indian Food Composition Tables 2017 give dietitians the nutrient values of 528 key Indian foods to plan with, and your exact target is a registered dietitian’s call.
Switching or Stopping
How long should I take GLP-1 for weight loss? There is no fixed end date. Obesity behaves like a long-term condition, and the trials show what happens when treatment stops.
This is where Indian users often feel misled by online stories that promise a three-month course. The trial data point the other way, and it is better to know that before starting than to discover it after stopping.
In the STEP 1 extension, people regained about two-thirds of the weight they had lost within a year of stopping semaglutide. In SURMOUNT-4, those switched from tirzepatide to placebo regained 14% of their body weight over the following year, while those who continued kept losing.
So how long to take Mounjaro or semaglutide is a decision you revisit with your doctor at every review. Some users stay on a maintenance dose for years. Others, with their doctor’s guidance, try a lower dose once their weight and habits are steady, although evidence on step-down plans is still limited.
Reviews look at more than the scale. A doctor checks whether HbA1c, blood pressure, liver tests and waist size have moved, how you are eating, and whether side effects have settled. Those markers often shape the next step more than the weight alone.
Switching between the two happens for reasons like side effects or a long plateau. Neither label gives a dose-for-dose conversion chart, so doctors plan the move around the new medicine’s own escalation steps and how you tolerate it.
Moving from a branded pen to a generic of the same molecule is a different kind of switch. The medicine is the same, but the device, the strength per pen or vial, and the injection technique can differ, so ask your doctor or pharmacist to walk you through it before the first dose.
Regain after stopping reflects biology and has little to do with willpower. That is why good programs keep the food, sleep, and strength work going after the last injection.
Planning for that early helps. Users who build a steady routine during treatment, such as a protein-forward breakfast, a walk after dinner, and two or three strength sessions a week, have habits to lean on if the dose is ever lowered.
| Conclusion |
| India has three approved prescription options for weight management: semaglutide, tirzepatide, and orlistat. In a supervised program, like MetaGO’s, a doctor checks eligibility against both trial criteria and Indian thresholds, matches the medicine to your health history, climbs the dose slowly, watches bloods, muscle, and side effects, and plans for the long term, including what happens if you stop. |
FAQs
1. Which medications are used in supervised programs?
Mainly semaglutide and tirzepatide, both once-weekly injections, plus orlistat, an oral capsule. These are the three medicines the Health Ministry has listed as CDSCO-approved for weight management. Liraglutide, dulaglutide, and oral semaglutide are licensed in India for type 2 diabetes, not for weight management on its own.
2. How do doctors choose between them?
They confirm eligibility first, then weigh diabetes, heart disease, past pancreatitis or gallbladder problems, thyroid cancer history, other medicines, and digestive tolerance. In SURMOUNT-5, tirzepatide led to more weight loss than semaglutide, while semaglutide has heart-outcome data from SELECT. The right choice depends on the individual.
3. How is the dose increased?
Tirzepatide starts at 2.5 mg weekly for four weeks, moves to 5 mg, then rises in 2.5 mg steps every four weeks or more, up to 15 mg. Semaglutide moves through 0.25, 0.5, 1 and 1.7 mg, four weeks each, reaching 2.4 mg from week 17. Your doctor can pause a step if side effects are strong.
4. What is monitored during treatment?
Baseline bloods usually cover HbA1c, lipids, liver, thyroid and kidney function. Follow-ups track weight, waist, blood pressure, blood sugar in people with diabetes, digestive side effects, warning signs of pancreatitis or gallbladder trouble, muscle strength, and vitamin D, B12 and iron when eating drops sharply.
5. How long do people stay on medication?
Often for the long term. In the STEP 1 extension, people regained about two-thirds of their lost weight within a year of stopping, and SURMOUNT-4 showed similar regain after stopping tirzepatide. Duration is set and reviewed with your doctor.
| Medical Disclaimer |
| This article is for general education and is not medical advice, diagnosis or treatment. The medicines discussed are prescription-only in India and should be started, adjusted or stopped only under the supervision of a qualified doctor who knows your full health history. Never change a dose on your own. If you have severe abdominal pain, persistent vomiting, signs of dehydration or any symptom that worries you, seek medical help promptly. |
